iwCLL 2017 | Safety profiles of idelalisib, duvelisib and TGR-1202 in treating CLL

Jennifer Brown

Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, reviews the efficacy and safety profile of the PI3K delta inhibitor, idelalisib, in the treatment of chronic lymphocytic leukemia (CLL), noting that due to the difficulty in managing its toxicity profiles, the drug has been limited to treating relapsed refractory CLL. Other drugs that are evaluated by Dr. Brown include the PI3K gamma/delta inhibitor, duvelisib, and the novel drug, TGR-1202. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

Share this video